The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 517-525

  Akerley, Wallace L ^a,b   Nelson, Richard E ^b,c   Cowie, Robin H ^d   Spinella, Dominic G ^d   Hornberger, John ^e,f  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BIODESIX INC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Cedar Associates   (United States)

Author keywords

Biomarker; Decision impact; Erlotinib; Mass spectrometry; Non small cell lung cancer; Proteomics

Indexed keywords

ERLOTINIB;

ADVANCED CANCER; AGED; ARTICLE; BEHAVIOR CHANGE; BLOOD ANALYSIS; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEOME; PROTEOMICS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 84876246352     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.782282     Document Type: Article

References (20)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society, 2012. Available at: http://www.cancer.org/[Last accessed 15 December 2012]
2. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute, 2013. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/[Last accessed 30 January 2013]
3. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer, V.2.2013. National Comprehensive Cancer Network Inc., 2013. Available at: www.nccn.org [Last accessed 21 January 2013]
4. Shepherd F, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall- cell lung cancer. N Engl J Med 2005;353:123-32
5. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80
6. Dacic S, Shuai Y, Yousem S, et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-68
7. Mok T, Wu Y, Thongprasert S, et al. Phase III, randomized, open-label, firstline study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS). N Eng J Med 2009;361: 947-57
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010;11:521-9
10. Batten LS, Winter HS, Hardie CL, et al. Clinicians' views on introducing epidermal growth factor receptor testing in New Zealand. Asia Pac J Clin Oncol 2012. Published online 11 October 2012, doi: 10.1111/ajco.12012
11. Hirsh V, Melosky B, Goss G, et al. A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol 2012;19:78-90
12. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the MSPT plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21. J Thorac Oncol 2012;7:1653-60
13. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-46
14. Stinchcombe T, Roder J, Peterman A et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (Age 70 Years or older) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2013;8:443-51
15. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of nonsmall cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010;5:169-78
16. Hornberger J, Doberne J, Chien R. Laboratory-developed test - SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks. Genet Test Mol Bio 2012;16:605-14
17. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14
18. Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont Health Technol Assess Ser 2010;10:1-48
19. Seltzer MA, Yap CS, Silverman DH, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002;43:752-6
20. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012;104:1068-79